The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies
Open accessAbstract
The development of effective treatment strategies for most forms of acute myeloid leukemia (AML) has languished for the past several decades. There are a number of reasons for this, but key among them is the considerable heterogeneity of this disease and the paucity of molecular markers that can be used to predict clinical outcomes and responsiveness to different therapies. The recent large-scale sequencing of AML genomes is now providing opportunities for patient stratification and personalized approaches to treatment that are based on individual mutational profiles. It is particularly notable that studies by The Cancer Genome Atlas and others have determined that 44% of patients with AML exhibit mutations in genes that regulate methylation of genomic DNA. In particular, frequent mutation has been observed in the genes encoding DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2), as well as Tet oncogene family member 2. This review will summarize the incidence of these mutations, their impact on biochemical functions including epigenetic modification of genomic DNA and their potential usefulness as prognostic indicators. Importantly, the presence of DNMT3A, IDH1 or IDH2 mutations may confer sensitivity to novel therapeutic approaches, including the use of demethylating agents. Therefore, the clinical experience with decitabine and azacitidine in the treatment of patients harboring these mutations will be reviewed. Overall, we propose that understanding the role of these mutations in AML biology will lead to more rational therapeutic approaches targeting molecularly defined subtypes of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citationIDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Slovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Dnmt3a is essential for hematopoietic stem cell differentiation
Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833
Yan, X.-J., Xu, J., Gu, Z.-H., Pan, C.-M., Lu, G., Shen, Y., Shi, J.-Y., Zhu, Y.-M., Tang, L., Zhang, X.-W., et al. (2011) · Nature Genetics · doi:10.1038/ng.788 · Cited by 813
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E. A., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170589 · Cited by 781
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationMarcucci, G., Maharry, K., Wu, Y.-Z., Radmacher, M. D., Mrózek, K., Margeson, D., Holland, K. B., Whitman, S. P., Becker, H., Schwind, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3730 · Cited by 763
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Dores, G. M., Devesa, S. S., Curtis, R. E., Linet, M. S., & Morton, L. M. (2012) · Blood · doi:10.1182/blood-2011-04-347872 · Cited by 636
Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
Marcucci, G., Haferlach, T., & Döhner, H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2554 · Cited by 570
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationRecurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Blum, W., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S., Liu, S., Havelange, V., Becker, H., Schaaf, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Abbas, S., Lugthart, S., Kavelaars, F. G., Schelen, A., Koenders, J. E., Zeilemaker, A., van Putten, W. J. L., Rijneveld, A. W., Löwenberg, B., & Valk, P. J. M. (2010) · Blood · doi:10.1182/blood-2009-11-250878 · Cited by 393
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia
Thol, F., Damm, F., Lüdeking, A., Winschel, C., Wagner, K., Morgan, M., Yun, H., Göhring, G., Schlegelberger, B., Hoelzer, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4894 · Cited by 374
IDH mutations in glioma and acute myeloid leukemia
Dang, L., Jin, S., & Su, S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 370
Jankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311019 · Cited by 330
Shen, Y., Zhu, Y.-M., Fan, X., Shi, J.-Y., Wang, Q.-R., Yan, X.-J., Gu, Z.-H., Wang, Y.-Y., Chen, B., Jiang, C.-L., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343988 · Cited by 323
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationAkalin, A., Garrett-Bakelman, F. E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Milne, T. A., Huang, Y., Biswas, D., Hess, J. L., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002781 · Cited by 296
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A., & Beer, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285
Traina, F., Visconte, V, Elson, P., Tabarroki, A., Jankowska, A. M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C. L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 269
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
Ribeiro, A. F. T., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., Figueroa, M. E., Zeilemaker, A., Melnick, A., Löwenberg, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367961 · Cited by 262
Epigenetic targets of bioactive dietary components for cancer prevention and therapy
Meeran, S. M., Ahmed, A., & Tollefsbol, T. O. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0011-5 · Cited by 255
A novel hierarchical prognostic model of AML solely based on molecular mutations
Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.-M., Staib, P., Serve, H., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419622 · Cited by 252
Marcucci, G., Metzeler, K. H., Schwind, S., Becker, H., Maharry, K., Mrózek, K., Radmacher, M. D., Kohlschmidt, J., Nicolet, D., Whitman, S. P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2092 · Cited by 251
Array-based genomic resequencing of human leukemia
Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y. L., Ueno, T., Soda, M., Hamada, T., Haruta, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.117 · Cited by 249
Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia
Abdel-Wahab, O., & Levine, R. L. (2013) · Blood · doi:10.1182/blood-2013-01-451781 · Cited by 249
Kosmider, O., Gelsi-Boyer, V, Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 247
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Levis, M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.220 · Cited by 243
Wagner, K., Damm, F., Göhring, G., Görlich, K., Heuser, M., Schäfer, I., Ottmann, O., Lübbert, M., Heit, W., Kanz, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6899 · Cited by 241
Hou, H.-A., Kuo, Y.-Y., Liu, C.-Y., Chou, W.-C., Lee, M. C., Chen, C.-Y., Lin, L.-I., Tseng, M.-H., Huang, C.-F., Chiang, Y.-C., et al. (2012) · Blood · doi:10.1182/blood-2011-07-369934 · Cited by 241
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
National Cancer Institute (2020) · Definitions · doi:10.32388/b2g8ub · Cited by 217
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210
5-hydroxymethylcytosine and its potential roles in development and cancer
Pfeifer, G. P., Kadam, S., & Jin, S.-G. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-10 · Cited by 203
DiNardo, C. D., Propert, K. J., Loren, A. W., Paietta, E., Sun, Z., Levine, R. L., Straley, K. S., Yen, K., Patel, J. P., Agresta, S., et al. (2013) · Blood · doi:10.1182/blood-2013-03-493197 · Cited by 198
Self-citationThol, F., Weissinger, E. M., Krauter, J., Wagner, K., Damm, F., Wichmann, M., Gohring, G., Schumann, C., Bug, G., Ottmann, O., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.025494 · Cited by 191
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Metzeler, K. H., Walker, A., Geyer, S., Garzon, R., Klisovic, R. B., Bloomfield, C. D., Blum, W., & Marcucci, G. (2012) · Leukemia · doi:10.1038/leu.2011.342 · Cited by 186
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
Self-citationAcute Myeloid Leukemia With IDH1 or IDH2 Mutation
Patel, K. P., Ravandi, F., Ma, D., Paladugu, A., Barkoh, B. A., Medeiros, L. J., & Luthra, R. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpd7nr2rmnqdvf · Cited by 178
Gupta, V., Tallman, M. S., & Weisdorf, D. J. (2011) · Blood · doi:10.1182/blood-2010-10-265603 · Cited by 178
Chou, W.-C., Lei, W.-C., Ko, B.-S., Hou, H.-A., Chen, C.-Y., Tang, J.-L., Yao, M., Tsay, W., Wu, S.-J., Huang, S.-Y., et al. (2011) · Leukemia · doi:10.1038/leu.2010.267 · Cited by 177
Gaidzik, V. I., Schlenk, R. F., Paschka, P., Stölzle, A., Späth, D., Kuendgen, A., von Lilienfeld-Toal, M., Brugger, W., Derigs, H. G., Kremers, S., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461624 · Cited by 177
Tefferi, A., Jimma, T., Sulai, N. H., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., & Pardanani, A. (2012) · Leukemia · doi:10.1038/leu.2011.253 · Cited by 172
Self-citationRocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 167
DNMT3A mutations in myeloproliferative neoplasms
Stegelmann, F., Bullinger, L., Schlenk, R. F., Paschka, P., Griesshammer, M., Blersch, C., Kuhn, S., Schauer, S., Döhner, H., & Döhner, K. (2011) · Leukemia · doi:10.1038/leu.2011.77 · Cited by 151
Patnaik, M. M., Hanson, C. A., Hodnefield, J. M., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R. P., Pardanani, A. D., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.298 · Cited by 147
Self-citationRole of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
Chan, S. M., & Majeti, R. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1407-8 · Cited by 142
Renneville, A., Boissel, N., Nibourel, O., Berthon, C., Hélevaut, N., Gardin, C., Cayuela, J., Hayette, S., Reman, O., Contentin, N., et al. (2012) · Leukemia · doi:10.1038/leu.2011.382 · Cited by 139
Origins of aberrant DNA methylation in acute myeloid leukemia
Schoofs, T., Berdel, W. E., & Müller‐Tidow, C. (2013) · Leukemia · doi:10.1038/leu.2013.242 · Cited by 138
IDH mutations in acute myeloid leukemia
Rakheja, D., Konoplev, S. N., Medeiros, L. J., & Chen, W. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.05.003 · Cited by 135
Abdel-Wahab, O., Pardanani, A., Rampal, R., Lasho, T. L., Levine, R. L., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2011.82 · Cited by 134
Self-citationFathi, A. T., Sadrzadeh, H., Borger, D. R., Ballen, K. K., Amrein, P. C., Attar, E. C., Foster, J., Burke, M. E., Lopez, H. U., Matulis, C. R., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438267 · Cited by 125
Khan, S. I., Aumsuwan, P., Khan, I. A., Walker, L., & Dasmahapatra, A. K. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200378c · Cited by 124
Lin, J., Yao, D., Qian, J., Chen, Q., Qian, W., Li, Y., Yang, J. C., Wang, C.-Z., Chai, H., Qian, Z. Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026906 · Cited by 121
Chotirat, S., Thongnoppakhun, W., Promsuwicha, O., Boonthimat, C., & Auewarakul, C. U. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-5 · Cited by 116
Patnaik, M. M., Lasho, T. L., Finke, C. M., Gangat, N., Caramazza, D., Holtan, S. G., Pardanani, A. D., Knudson, R. A., Ketterling, R. P., Chen, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.105 · Cited by 114
Self-citationIDH1 and IDH2 mutations in pediatric acute leukemia
Andersson, A., Miller, D. W., Lynch, J. A., Lemoff, A. S., Cai, Z., Pounds, S. B., Radtke, I., Yan, B., Schuetz, J. D., Rubnitz, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.133 · Cited by 98
Hou, H.-A., Lin, C.-C., Chou, W.-C., Liu, C.-Y., Chen, C.-Y., Tang, J.-L., Lai, Y.-J., Tseng, M.-H., Huang, C.-F., Chiang, Y.-C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.236 · Cited by 95
Negrotto, S., Ng, K. P., Jankowska, A. M., Bodo, J., Gopalan, B., Guinta, K., Mulloy, J. C., Hsi, E., Maciejewski, J., & Saunthararajah, Y. (2012) · Leukemia · doi:10.1038/leu.2011.207 · Cited by 90
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
Yan, P. S., Frankhouser, D. E., Murphy, M., Tam, H.-H., Rodriguez, B. A. T., Curfman, J. P., Trimarchi, M. P., Geyer, S. M., Wu, Y.-Z., Whitman, S. P., et al. (2012) · Blood · doi:10.1182/blood-2012-05-429175 · Cited by 88
Landmark analysis of DNMT3A mutations in hematological malignancies
Roller, A., Grossmann, V., Bacher, U., Poetzinger, F., Weißmann, S., Nadarajah, N., Boeck, L., Kern, W., Haferlach, C., Schnittger, S., et al. (2013) · Leukemia · doi:10.1038/leu.2013.65 · Cited by 88
Damm, F., Thol, F. R., Hollink, I. H. I. M., Zimmermann, M., Reinhardt, K., van den Heuvel‐Eibrink, M. M., Zwaan, C. M., de Haas, V., Creutzig, U., Klusmann, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.142 · Cited by 87
Rare occurrence of DNMT3A mutations in myelodysplastic syndromes
Thol, F. R., Winschel, C., Lüdeking, A., Yun, H., Friesen, I., Damm, F., Wagner, K., Krauter, J., Heuser, M., & Ganser, A. (2011) · Haematologica · doi:10.3324/haematol.2011.045559 · Cited by 78
Marková, J., Michková, P., Burčková, K., Březinová, J., Michalova, K., Dohnalova, A., Maaloufová, J., Soukup, P., Vı́tek, A., Cetkovský, P., et al. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01716.x · Cited by 74
Dinardo, C. D., Patel, K. P., Garcia‐Manero, G., Luthra, R., Pierce, S. A., Borthakur, G. M., Jabbour, E. J., Kadia, T. M., Pemmaraju, N., Konopleva, M. Y., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.855309 · Cited by 72
Fernández‐Mercado, M., Yip, B. H., Pellagatti, A., Davies, C. H., Larráyoz, M. J., Kondo, T., Pérez, C., Killick, S. B., McDonald, E.-J., Odero, M. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042334 · Cited by 64
Sulai, N. H., Jimma, T., Lasho, T. L., Finke, C. M., Knudson, R. A., McClure, R. F., Pardanani, A. D., & Tefferi, A. (2011) · Blood · doi:10.1182/blood.v118.21.1751.1751 · Cited by 61
Self-citationMims, A. S., Walker, A. R., Huang, X., Sun, J., Wang, H., Santhanam, R., Dorrance, A. M., Walker, C. J., Hoellerbauer, P., Tarighat, S. S., et al. (2012) · Leukemia · doi:10.1038/leu.2012.342 · Cited by 60
Ravandi, F., Patel, K. P., Luthra, R., Faderl, S. H., Konopleva, M. Y., Kadia, T. M., Brandt, M., Pierce, S. A., Kornblau, S. M., Andreeff, M., et al. (2011) · Cancer · doi:10.1002/cncr.26580 · Cited by 55
Ostronoff, F., Othus, M. K. D., Ho, P. A., Kutny, M. A., Geraghty, D. E., Petersdorf, S. H., Godwin, J. E., Willman, C. L., Radich, J. P., Appelbaum, F. R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.168 · Cited by 53
Hájková, H., Marková, J., Haškovec, C., Šárová, I., Fuchs, O., Kostečka, A., Cetkovský, P., Michalova, K., & Schwarz, J. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.05.012 · Cited by 47
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia
Caramazza, D., Lasho, T. L., Finke, C. M., Gangat, N., Dingli, D., Knudson, R. A., Siragusa, S. M., Hanson, C. A., Pardanani, A. D., Ketterling, R. P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.213 · Cited by 36
Self-citationEwalt, M. D., Galili, N., Mumtaz, M. A., Churchill, M., Rivera, S., Borot, F., Raza, A., & Mukherjee, S. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.7 · Cited by 35
Koszarska, M., Bors, A., Feczko, A., Meggyesi, N., Bátai, Á., Csomor, J., Ádám, E., Kozma, A., Orbán, T. I., Lovas, N., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.736981 · Cited by 32
Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
Brecqueville, M., Cervera, N., Gelsi‐Boyer, V., Murati, A., Adélaı̈de, J., Chaffanet, M., Rey, J., Vey, N., Mozziconacci, J., & Birnbaum, D. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.15 · Cited by 27
Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase
Popovici-Müller, J. V., Shipps, G. W., Rosner, K. E., Deng, Y., Wang, T., Curran, P. J., Brown, M. A., Siddiqui, M. A., Cooper, A. B., Duca, J. S., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.087 · Cited by 27
Perugini, M., Iarossi, D. G., Kok, C. H., Cummings, N. J., Diakiw, S. M., Brown, A. L., Danner, S., Bardy, P., To, L. B., Wei, A. H., et al. (2012) · Leukemia · doi:10.1038/leu.2012.346 · Cited by 27
Cited by
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
DNA methylation profiles in cancer diagnosis and therapeutics
Pan, Y., Liu, G., Zhou, F., Su, B., & Li, Y. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0467-0 · Cited by 373
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. (2017) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 350
Epigenetic drivers of tumourigenesis and cancer metastasis
Chatterjee, A., Rodger, E. J., & Eccles, M. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.004 · Cited by 328
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
DiNardo, C. D., Ravandi, F., Agresta, S., Konopleva, M., Takahashi, K., Kadia, T., Routbort, M., Patel, K. P., Brandt, M., Pierce, S., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24072 · Cited by 325
Metadata
- Authors
- Im, A. P., Sehgal, A. R., Carroll, M. P., Smith, B. D., Tefferi, A., Johnson, D. E., & Boyiadzis, M.
- Venue
- Leukemia
- Published
- 2014-04-04
- Volume
- 28
- Issue
- 9
- Pages
- 1774-1783
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2063092678
- Cited by
- 267
- References
- 102
- FWCI
- 21.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.